Analyzing Aldeyra Therapeutics (NASDAQ:ALDX) and Apollomics (NASDAQ:APLM)

Aldeyra Therapeutics (NASDAQ:ALDX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Volatility and Risk

Aldeyra Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Valuation and Earnings

This table compares Aldeyra Therapeutics and Apollomics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$37.54 million	($0.51)	-7.14
Apollomics	$1.22 million	14.83	-$172.60 million	N/A	N/A

Aldeyra Therapeutics has higher earnings, but lower revenue than Apollomics.

Analyst Ratings

This is a summary of recent ratings for Aldeyra Therapeutics and Apollomics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	0	0	3	0	3.00
Apollomics	0	0	1	0	3.00

Aldeyra Therapeutics presently has a consensus price target of $9.33, suggesting a potential upside of 156.41%. Apollomics has a consensus price target of $2.00, suggesting a potential upside of 889.61%. Given Apollomics’ higher probable upside, analysts plainly believe Apollomics is more favorable than Aldeyra Therapeutics.

Insider & Institutional Ownership

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Aldeyra Therapeutics and Apollomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-24.69%	-20.26%
Apollomics	N/A	N/A	N/A

Summary

Aldeyra Therapeutics beats Apollomics on 5 of the 9 factors compared between the two stocks.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

About Apollomics

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.